Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mothercare secures Turkish licence deal

(Sharecast News) - Mothercare has secured a licence agreement with a leading Turkish retailer, the UK business announced on Monday. The AIM-listed mother and baby retailer said it struck the 10-year deal with Ebebek, which has 280 stores and an online business in Turkey, producing revenues of around £400m.

The agreement gives Ebebek exclusive right to use the Mothercare brand in Turkey.

Mothercare is also able to re-brand certain Ebebek own-brand products to sell under its own branding in territories where the Turkish retailer does not trade.

As well as its Turkish portfolio, Ebebek recently opened three stores in the UK.

Clive Whiley, chair, said the deal was "evidence of the strength, inherent value and global appeal" of the Mothercare brand.

He continued: "We are in discussions with several other parties to further restore critical mass alongside delivering our other core objectives.

"The underlying business continues to prove its resilience."

Mothercare is looking to secure a number of partners worldwide, and last October struck a £30m joint venture deal with Indian giant Reliance Industries.

However, full-year revenues and earnings have tumbled, as geopolitical tensions in the Middle East weigh heavily on franchise partners in the region.

Mothercare's long-running partnership with Boots in the UK is also coming to an end this year.

As at 0930 BST, shares in Mothercare were up 4% at 2.86p, while Ebebek's Istanbul-listed stock was down 1%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.